How to Set Up a UAE Offshore Company in 2026: A Complete Guide
22 May, 2026How Qatar’s 2026 Sports Strategy Creates Business Opportunities
22 May, 2026Table of Contents
Introduction
Turkey’s pharmaceutical market is one of the fastest-growing in the region, driven by a large population, increasing healthcare spending, and a strategic geographic position. For international drug manufacturers, understanding the local regulatory environment is crucial for market access. In 2026, Turkey introduced significant changes to its pharmaceutical import licensing framework, aiming to streamline processes, enhance local production, and ensure drug security. This article explores how Turkey’s pharmaceutical import licensing has changed in 2026, what these reforms mean for foreign companies, and how to navigate the new requirements.
The New Licensing Framework in 2026
The Turkish Medicines and Medical Devices Agency (TITCK) implemented a revised import licensing system effective January 1, 2026. The changes are part of a broader strategy to align with international standards while promoting domestic manufacturing. Key alterations include updated application procedures, stricter quality documentation, and a shift towards digitalization.
Digital Application Portal
One of the most notable changes is the mandatory use of the new e-licensing portal for all import license submissions. Paper applications are no longer accepted. The portal integrates with other government databases, allowing real-time verification of company registration, product approvals, and Good Manufacturing Practice (GMP) certificates. This reduces processing times from an average of 90 days to 45 days for standard applications.
Revised Documentation Requirements
In 2026, the list of required documents for import licenses has been updated. Applicants must now submit:
- Electronic Common Technical Document (eCTD) format for product dossiers.
- GMP certificates from the country of origin, apostilled or notarized, and translated into Turkish.
- Proof of local representation – a legal representative or distributor based in Turkey.
- Stability data covering at least 12 months at the time of application.
- Batch release certificates for each batch imported.
Missing any of these documents leads to automatic rejection, whereas previously, applicants could submit supplementary materials within a grace period.
Changes in Licensing Categories
The 2026 reform redefined the categories of import licenses. There are now three distinct types:
- Standard Import License – for finished pharmaceutical products intended for human use.
- Bulk/Active Pharmaceutical Ingredient (API) License – for importing raw materials used in local manufacturing.
- Orphan Drug License – for drugs treating rare diseases, with expedited review and reduced fees.
Each category has specific requirements and validity periods. Standard licenses are valid for 3 years, API licenses for 5 years, and orphan drug licenses for 2 years, renewable.
Impact on Foreign Manufacturers
How has Turkey’s pharmaceutical import licensing changed in 2026 from the perspective of international companies? The reforms present both opportunities and challenges.
Positive Developments
- Faster processing – the digital system cuts down bureaucratic delays.
- Clearer guidelines – reduced ambiguity on documentation.
- Orphan drug incentives – lower fees and priority review encourage niche products.
- API licensing – supports integration with local production, potentially reducing costs.
Challenges to Anticipate
- Stricter compliance – non-negotiable document requirements mean no second chances.
- Local representation – mandatory, adding overhead for smaller firms.
- Translation requirements – all documents must be in Turkish, including technical data.
- Cost of digital transition – adapting to eCTD format may require software investment.
Strategic Recommendations for Compliance
To successfully navigate the 2026 changes, pharmaceutical companies should:
- Engage a local regulatory consultant familiar with TITCK procedures.
- Digitize your dossier in eCTD format well in advance.
- Secure a reliable local partner for representation and distribution.
- Plan for stability studies to meet the 12-month data requirement.
- Monitor TITCK announcements for any further updates or transitional provisions.
Conclusion
Turkey’s pharmaceutical import licensing has changed significantly in 2026, moving toward a more digital, transparent, and stringent system. While the reforms aim to improve efficiency and safety, they also demand higher compliance from foreign manufacturers. Understanding how Turkey’s pharmaceutical import licensing has changed in 2026 is essential for any company looking to enter or expand in this promising market. By preparing thoroughly and adapting to the new requirements, international players can continue to benefit from Turkey’s growing pharmaceutical sector.